Cinacalcet Tablet, Film Coated
Product Images NDC 72865-150

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Cinacalcet (NDC 72865-150). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Xlcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30mg-container-label (30mg Container Label)

Label for Cinacalcet Tablets 30 mg by XLCare Pharmaceuticals Inc. The label shows a film-coated oral tablet strength of 30 mg in a bottle of 30 tablets. It includes storage instructions and manufacturer details: made by Evaric Pharmaceuticals Inc., Hauppauge, New York, and manufactured for XLCare Pharmaceuticals Inc., Lawrenceville, GA. The NDC code is 72865-150-30.*

FDA Label Image

60mg-container-label (60mg Container Label)

Label for Cinacalcet Tablets 60 mg film-coated tablets by XLCare Pharmaceuticals Inc. The package contains 30 tablets. Label includes dosage strength, NDC 72865-151-30, storage instructions at 20° to 25°C, and manufacturer information for XLCare Pharmaceuticals and Evaric Pharmaceuticals.*

FDA Label Image

90mg-container-label (90mg Container Label)

Label for Cinacalcet Tablets 90 mg, film-coated oral tablets, supplied by XLCare Pharmaceuticals Inc. The label shows a package count of 30 tablets, includes the NDC 72865-152-30, and details storage instructions, manufacturer information, and barcode. The label indicates prescription use only.*

FDA Label Image

Figure-of-cinacalcet-1 (Figure Of Cinacalcet 1)

A line graph comparing ionized parathyroid hormone (iPTH) levels (pg/mL) over 26 weeks between Cinacalcet and placebo groups. The graph shows a decreasing trend in iPTH levels for the Cinacalcet group, starting around 750 pg/mL and declining to around 400 pg/mL, while the placebo group's iPTH remains relatively stable around 700 pg/mL. Error bars indicate variability at each time point.*

FDA Label Image

Figure-of-cinacalcet-2 (Figure Of Cinacalcet 2)

A line graph comparing Ca x P levels (mg/dL) over 26 weeks between a Placebo group and a Cinacalcet treatment group. The y-axis shows Ca x P levels, and the x-axis shows time in weeks. The Cinacalcet group shows a decrease in Ca x P levels over time, while the Placebo group remains relatively stable.*

FDA Label Image

Figure3 (Figure3)

A line graph showing serum calcium levels (mg/dL) over 80 weeks in patients with parathyroid carcinoma. The x-axis represents time in weeks with titration and maintenance phases labeled, and the y-axis shows calcium concentration. Data points include error bars and sample sizes per time point are noted below the x-axis.*

FDA Label Image

Figure4 (Figure4)

Line graph depicting serum calcium levels (mg/dL) over a period of 80 weeks in patients with intractable pHPT during titration and maintenance phases. The x-axis represents weeks, starting from baseline through week 80, while the y-axis measures calcium levels ranging from 8 to 16 mg/dL. Data points include error bars indicating variability, with patient numbers at each time point noted below the x-axis.*

FDA Label Image

Structure (Structure)

Chemical structure of the active ingredient Cinacalcet hydrochloride shown with its molecular framework and the hydrochloride (HCl) component.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.